Active substance
Mefenamic acid
- SFDA 14
- US FDA 6
- Health Canada 1
- US price lines 1
- NHS prices 3
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| FENAM 250MG TAB | 250 mg | Film-coated tablet · Oral use | 20 Blister | SAR 5.85 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| FENAM 50MG-5ML SYRUP | 10 mg/ml | Syrup · Oral use | 1 Bottle | SAR 12.60 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| FENAM FORTE 500MG TAB | 500 mg | Film-coated tablet · Oral use | 20 Blister | SAR 9.95 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| FENAMIC 250 MG CAP | 250 mg | Capsule · Oral use | 24 Blister | SAR 5.65 | Generic · Prescription | KUWAIT SAUDI PHARMACEUTICAL INDUSTRIES | Valid |
| PONSTAN FORTE 500 mg film-coated tablet | 500 mg | Film-coated tablet · Oral use | 20 Blister | SAR 15.30 | NCE · Prescription | PFIZER | Valid |
| FENDOL 250 MG CAPSULE | 250 mg | Capsule · Oral use | 20 Blister | SAR 4.55 | NCE · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| FENDOL 50MG-5ML SUSP | 10 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 8.65 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| FENDOL D.S.TAB 500MG | 500 mg | Film-coated tablet · Oral use | 20 Blister | SAR 7.35 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| MAFEPAIN 500MG TAB | 500 mg | Film-coated tablet · Oral use | 20 Blister | SAR 8.95 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| PANGESIC 250MG CAPS | 250 mg | Capsule · Oral use | 20 Blister | SAR 4.10 | Generic · Prescription | Ram Pharmaceutical Industries | Withdrawn by MAH · Not Marketed |
| PONSTAN SYRUP 50MG-5ML | 10 mg/ml | Syrup · Oral use | 1 Bottle | SAR 19.90 | NCE · Prescription | PARK-DAVIS | Withdrawn by MAH · Not Marketed |
| TABIGESIC 250MG TAB | 250 mg | Tablet · Oral use | 20 Blister | SAR 4.00 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| TABIGESIC 50MG-5ML SUSP. | 10 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 11.35 | NCE · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| TABIGESIC FORTE TAB | 500 mg | Tablet · Oral use | 20 Blister | SAR 8.10 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE PANCREATITIS-PAIN MANAGEMENT; ANKYLOSING SPONDYLITIS; CHRONIC PANCREATITIS; DENTAL ABSCESS-DENTAL PAIN; ENDOMETRIOSIS; ENTEROPATHIC ARTHROPATHIES, UNSPECIFIED SITE REACTIVE ARTHROPATHY, UNSPECIFIED; EPIDERMOLYSIS BULLOSA; JUVENILE IDIOPATHIC ARTHRITIS (JIA); LOW BACK PAIN; MENSTRUAL DISORDERS; MIGRAINE/ HEADACHE; MUCOSAL ULCERATION-SUPPORTIVE AGENTS; NON-INFECTIOUS UVEITIS; OSTEOARTHRITIS; PAIN MANAGEMENT IN CANCER PATIENTS; POSTOPERATIVE PAIN; PSORIATIC ARTHRITIS; RENAL AND URETERIC STONES; RHEUMATOID ARITHRITIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PONSTEL | 250MG | capsule · oral | AVION PHARMS | Prescription | 28 Mar 1967 |
| MEFENAMIC ACID | 250MG | capsule · oral | MICRO LABS | Prescription | 19 Nov 2010 |
| MEFENAMIC ACID | 250MG | capsule · oral | LUPIN LTD | Prescription | 22 Jul 2011 |
| MEFENAMIC ACID | 250MG | capsule · oral | AJENAT PHARMS | Prescription | 2 Jun 2014 |
| MEFENAMIC ACID | 250MG | capsule · oral | MPP PHARMA | Discontinued | 5 Feb 2013 |
| MEFENAMIC ACID | 250MG | capsule · oral | CHARTWELL RX | Discontinued | 18 Sep 2020 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| MEFENAMIC | 02229452 | 250 MG | CAPSULE · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | MEFENAMIC ACID 250 MG CAPSULE | $0.94789 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Mefenamic acid 250mg capsules | £12.72 | 100 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Mefenamic acid 250mg tablets | £7.22 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Mefenamic acid 500mg tablets | £14.94 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 31 Dec 2025 PONSTEL — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.